In this episode Professor Vibeke Strand discusses polymyalgia rheumatica (or PMR), a common inflammatory rheumatic disease that significantly impairs patients’ quality of life, causing fatigue, pain, and physical disability, especially in relapsing cases that often require long-term glucocorticoid treatment. However, these treatments come with considerable side effects, and many patients do not respond to treatment.We also cover her recent publication, which explores the patient reported outcomes of a trial using sarilumab, a monoclonal antibody targeting the inflammatory cytokine IL-6, which has now been approved for treatment of PMR in the USA.Read the full article:https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00041-4/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lanrheContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
--------
11:32
--------
11:32
Xue Li on access to biologics in the Asia-Pacific region
This is a joint podcast between The Lancet Rheumatology and The Lancet Regional Health - Western Pacific with Prof Xue Li. Biologics have become a mainstay of treatment in Rheumatology in Western populations, but in many parts of Asia, especially lower-and-middle-income countries, there remains substantial inequity in access due to differences in availability and affordability.In this episode, we explore the factors that may have delayed the popularisation of biologics in Asia, any recent policy changes and the role of biosimilars in this landscape.Read the full article:https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(22)00121-3/fulltext?dgcid=buzzsprout_icw_podcast_June_25_lanwpcContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
--------
19:31
--------
19:31
Sinisa Savic on treatment outcomes in VEXAS syndrome
In this podcast, Professor Savic talks about his recent publication that looks at treatment outcomes in patients with VEXAS syndrome, as well as what clinicians should look out for in patients (red flags), and future priorities for research.VEXAS syndrome (short for Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome) was first described in 2020. It’s a rare, and often-life threatening, inflammatory condition primarily affecting men. It's caused by a mutation in the UBA1 gene, leading to systemic inflammation and progressive bone marrow failure. The condition can manifest with a variety of symptoms, including fevers, fatigue, rashes, and joint pain, and can affect various organs and tissues.Read the full article:https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00034-7/fulltext?dgcid=buzzsprout_icw_podcast_June_25_lanrheContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
--------
12:07
--------
12:07
Fabian Müller and Melanie Hagen on a newly discovered toxicity of CD-19 targeting CAR T-cell therapy
This is the third and final episode of our mini-series on cell-based therapies in rheumatology, with Professor Fabian Müller and Dr Melanie Hagen from the Erlangen University, Germany. We discuss their recently published a study on a newly discovered toxicity of CD-19 targeting CAR T-cell therapy in patients with autoimmune disease, as well as the recent successes of CAR T-cell therapy, ideal patient selection, and future directions.Read the full article:https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00091-8/fulltext?dgcid=buzzsprout_icw_podcast_Jun_25_lanrheContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
--------
20:50
--------
20:50
Dominique Farge on allogeneic umbilical cord-derived mesenchymal stromal cells for systemic lupus erythematosus
This is the second episode of a mini series on cell-based therapies in rheumatology, with Prof. Dominique Farge discussing the use of allogeneic umbilical cord-derived mesenchymal stromal cells (MSCs) as treatment for systemic lupus erythematosus (SLE). We cover the limited options currently available for people with severe or refractory SLE, the complexities in using MSCs, Prof. Farge's recent study results, and how these results fit in with the evidence available, as well as the future for this area of research. You can find the study here:https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00298-4/fulltext?dgcid=buzzsprout_icw_podcast_25-04-25_lanrheContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Editors at The Lancet Rheumatology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from disorders of the immune system to sex and gender in research design, the transitional care for adolescent patients with rheumatic diseases to care for undocumented immigrants, and more.
Italia